Literature DB >> 3033051

Thyroid and pituitary hormone responses to TRH in advanced nonalcoholic liver disease.

D H Van Thiel, R Tarter, J S Gavaler, R R Schade, A Sanghvi.   

Abstract

Basal T4, T3, TSH, prolactin and growth hormone levels were determined in several groups: patients with postnecrotic cirrhosis with hepatocellular carcinoma (n = 14); patients with postnecrotic cirrhosis but without hepatocellular carcinoma (n = 26); cholangiolar carcinoma (n = 9); and normal controls age-matched to within 5 yr of the liver disease subjects studied. In addition, TRH stimulation (400 micrograms TRH) was performed; TSH, prolactin and growth hormone responses over a 180-min time interval were evaluated for each subject. The responses observed varied between liver disease groups. The presence or absence of hepatocellular carcinoma was found to determine, at least in part, the type of response observed. Similarly, the presence or absence of hepatic encephalopathy determined, and/or reflected, at least in part, the type of response observed. Finally, for purposes of continuity, basal and TRH-stimulated levels of TSH, prolactin, growth hormone, T4 and T3 are compared in 3 settings of cirrhosis: alcoholic, nonalcoholic postnecrotic cirrhosis, and postnecrotic cirrhosis with hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3033051     DOI: 10.1007/BF03346970

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Thyroid function and thyroid regulation in euthyroid men with chronic liver disease: evidence of multiple abnormalities.

Authors:  J R Green; E J Snitcher; N A Mowat; R P Ekins; L H Rees; A M Dawson
Journal:  Clin Endocrinol (Oxf)       Date:  1977-12       Impact factor: 3.478

2.  Serum T3 and reverse T3 levels in hepatic cirrhosis: relation to hepatocellular damage and normalization on improvement in liver dysfunction.

Authors:  U M Kabadi; B N Premachandra
Journal:  Am J Gastroenterol       Date:  1983-11       Impact factor: 10.864

3.  Letter: Reverse triiodothyronine in liver disease.

Authors:  R Kodding; J Janzen; E Schmidt; R D Hesch
Journal:  Lancet       Date:  1976-08-07       Impact factor: 79.321

Review 4.  Control of thyrotropin secretion in man.

Authors:  J M Hershman; J A Pittman
Journal:  N Engl J Med       Date:  1971-10-28       Impact factor: 91.245

5.  Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis.

Authors:  S Nomura; C S Pittman; J B Chambers; M W Buck; T Shimizu
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

6.  Serum thyroid hormone levels in patients with liver disease.

Authors:  G W Hepner; I J Chopra
Journal:  Arch Intern Med       Date:  1979-10

7.  Radioimmunoassay for serum thyroxine-binding globulin: results in normal subjects and in patients with hepatocellular carcinoma.

Authors:  M C Gershengorn; P R Larsen; J Robbins
Journal:  J Clin Endocrinol Metab       Date:  1976-05       Impact factor: 5.958

8.  Associations between diseases of the thyroid and the liver.

Authors:  R R Babb
Journal:  Am J Gastroenterol       Date:  1984-05       Impact factor: 10.864

9.  Patterns of hypothalamic-pituitary-gonadal dysfunction in men with liver disease due to differing etiologies.

Authors:  D H van Thiel; J S Gavaler; J A Spero; K M Egler; C Wright; A T Sanghvi; U Hasiba; J H Lewis
Journal:  Hepatology       Date:  1981 Jan-Feb       Impact factor: 17.425

Review 10.  Alcohol and sexual function.

Authors:  D H Van Thiel; J S Gavaler; P K Eagon; Y B Chiao; C F Cobb; R Lester
Journal:  Pharmacol Biochem Behav       Date:  1980       Impact factor: 3.533

View more
  1 in total

1.  Pituitary hormone circadian rhythm alterations in cirrhosis patients with subclinical hepatic encephalopathy.

Authors:  Dimitrios Velissaris; Menelaos Karanikolas; Andreas Kalogeropoulos; Ekaterini Solomou; Panagiotis Polychronopoulos; Konstantinos Thomopoulos; Chrissoula Labropoulou-Karatza
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.